DNA RESEARCH, GENETICS AND CELL BIOLOGY -- DNA RESEARCH, GENETICS AND CELL BIOLOGY -- CONTENTS -- PREFACE -- Chapter I MUTATION DETECTION IN TP53 GENE: ALTERNATIVES IN POINT MUTATION TECHNOLOGIES -- References -- Chapter II MUTATIONAL HOTSPOTS OF TP53 GENE ASSOCIATED TO DNA DAMAGE -- Abstract -- Glossary -- Introduction -- The Role of the TP53 Gene -- The p53 Protein -- TP53 Screening Techniques -- Implications of Mutational Hotspotsof TP53 Gene at Level of DNA Damage -- Conclusion -- References -- Chapter III DNA DAMAGE RELATED TO EXPOSURE TO OIL SPILLS: THE PRESTIGE EXPERIENCE -- Abstract -- 1. Introduction -- 2. Study Population -- 3. Exposure Evaluation -- 4. Effect Biomarkers -- 4.1. Comet Assay -- 4.2. Micronucleus Test -- 4.3. Sister Chromatid Exchanges -- 5. Susceptibility Biomarkers -- 5.1. Metabolic Genes -- 5.2. DNA Repair Genes -- Conclusion -- References -- Chapter IV THE BIGGEST WINNERS IN DNA AND PROTEIN SEQUENCE ANALYSIS: METAGENOMICS, DNA MICROARRAY, BIOSENSORS, MOLECULAR SUBTYPING, AND PHAGE RECOMBINANT PROBES -- Abstract -- Metagenomic Strategies for Uncultured Microbes -- Metagenomic DNA Strategies -- Metagenomic in Bacterial Communities -- Metagenomic in Virus Communities -- Characterization and Detection of DNA Hybridization by Using Metal Nanoparticles (NP) and Surface-Enhanced Vibrational Spectroscopy -- Application of DNA Microarray Technology -- Gene Expression and Microbial Identification in Food Bacterial Pathogens -- Possible Clinical Applications of DNA Microarray -- Looking Forward - The Future of DNA Microarray -- Recent Advances in the Molecular Subtyping of Bacterial Strains -- Enhanced PFGE-Based Subtyping Schemes for Clonal Serovars of the Salmonellae -- Enhanced DNA-Sequence Based Subtyping for Clonal Serovars of the Salmonellae -- Recombinant Phage Probes in Microbial Diagnostics.

Phage Display Technology -- Recombinant Phage Probes -- Applications -- Acknowledgment -- References -- Chapter V ROLE OF EFFECTORS ON HYPOXIA DUE TO NITRIC OXIDE PRODUCTION INHUMAN ALVEOLAR EPITHELIAL CELLS AND OXYGEN DEPLETION IN HUMAN HEPATOCYTES -- Abstract -- Introduction -- Materials and Methods -- Cell Culture -- Alveolar Cells Exposed to Cytokines and Cell Viability -- Nitric Oxide Assay -- NADPH Oxidase -- cAMP Dependent Calmodulin Mediated Phosphodiesterase Stimulation -- Superoxide Dismutase -- Hexose Monophosphate Shunt Activity -- Glutathione Reductase -- Results -- Nitric Oxide Production in Human Alveolar Epithelial Cells -- Cell Viabilityin Human Alveolar Epithelial Cells -- NADPH Oxidase Activity in Hypoxia -- cAMPPhosphodiesterase Activity in Hypoxia -- Superoxide Dismutase Activitiy in Hypoxia -- Hexose Monophosphate Shunt Activity in Hypoxia -- Glutathione Reductase (GSR) Enzyme Activity in Hypoxia -- Discussion -- References -- Chapter VI METHODS, STRATEGIES AND FACTS FOR IMPROVING THE ANALYSIS OF GENETIC VARIATIONS USING DNA ARRAYS -- Abstract -- Introduction -- Microarray-Definition -- Microarray- Nomenclature -- Microarray- Technology -- Some Limitations of Oligonucleotide Array Technology -- Tandem Hybridization on Oligonucleotide Microarrays -- Some Relevant Guidelines for the Design of Oligonucleotide Probes -- Selecting the Appropriated (Desired) Targets -- Deriving the Sequences of the Probes -- Validating the Specificity of the Probe -- Applications Developed for the Study of Organisms on DNA Arrays -- Barcode -- Organism Identification -- Metagenomics -- Resequencing -- Conclusion -- References -- Chapter VII PLASMA CELL DYSCRASIAS -- Introduction -- Definitions of Various Forms of Plasma Cell Dyscrasia (See Table 1) -- Plasmacytoma -- Monoclonal Gammopathy of Undetermined Significance (MGUS).

Smoldering Multiple Myeloma -- Symptomatic Multiple Myeloma -- Non-Secretory Multiple Myeloma -- Plasma Cell Leukemia -- Multiple Myeloma International Staging System -- Morphologic Variants of Neoplastic Plasma Cells (See Table 2) -- Immunophenotypic Features of Neoplastic Plasma Cells -- Immunophenotypic Techniques in Diagnosing Plasma -- Cell Dyscrasias -- Clinically Significant Molecular Abnormalities In Plasma Cell Myeloma (See Table 3) -- Chromosome 13 Abnormalities -- Del(17p) and P53 Abnormalities -- IMMUNOGLOBULIN HEAVY CHAIN (14q32) TRANSLOCATIONS -- General -- t(11 -- 14)(Q13 -- Q32)IGH/CCND1 -- t(4 -- 14)(P16 -- Q32) MMSET/IGH -- t(14 -- 16)(Q32 -- Q23) IGH/CMAF -- Other IGH Translocations -- Other Chromosomal Abnormalities -- Other Genetic Abnormalities -- A Practical Approach to Molecular Evaluation of MM -- Current Therapeutic Guidelines for MM -- Initial Therapy in Patients Eligible for Transplantation -- Initial Therapy in Patients not Eligible for Transplantation -- Hematopoietic Stem-Cell Transplantation -- Autologous Stem Cell Transplant (ASCT) -- Tandem Transplantation -- Allogeneic Transplantation -- Maintenance Therapy -- Treatment of High-Risk Myeloma -- Supportive Care -- References -- INDEX -- Blank Page.